


# Drug Renaissance

Next-generation sequencing (NGS) allows for analysis of the human genome, the complete set of genetic material within a human. The ways drugs are developed and diseases researched have changed markedly because of NGS. Additionally, tools associated with NGS are reducing the costs of disease while improving the accuracy of diagnosis and the efficacy of treatment.

**Sequencing Cost Per Genome Declining Rapidly**



Source: National Human Genome Research Institute. Forecast is based on Illumina CEO's estimate.

- Since 2001 the cost of genome sequencing has declined considerably, allowing for more widespread use of these methods. As NGS technology advances and enables larger and more complex research projects, the cost of genetic analysis will continue to come down.
- NGS has revolutionized drug development because researchers can now fully understand the effect of the human genome on disease as well as identify mutations to determine how best to treat diseases. Specifically, scientists are improving their understanding of cancer biology, discovering the causes of many heritable disorders and creating opportunities for preventive and predictive medicine.
- NGS has only begun to unlock scientists' understanding of biological systems. As NGS advances and more genetic data is collected, the research and development of drugs and diagnostic tools continue to accelerate.
- To potentially capitalize on NGS, investors might consider health care technology companies that develop NGS equipment or tools as well as companies that use NGS to advance the diagnosis or treatment of diseases.

The views expressed are the views of Fred Alger Management, Inc. ("FAM") and Alger Management, Ltd. ("AML") as of March 2018. These views are subject to change at any time and they do not guarantee the future performance of the markets, any security or any funds managed by Fred Alger Management, Inc. These views are not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. FAM serves as sub-advisor to AML.

Funds authorized by the Swiss Financial Market Supervisory Authority FINMA for distributing their shares publicly in Switzerland: for interested parties, fund regulations or the articles of incorporation, the key investor information document (KIID) and the full prospectus, in their current versions, as well as the annual and semi-annual reports are provided free of charge at the representative in Switzerland. ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich. Paying agent in Switzerland is Neue Helvetische Bank AG, Seefeldstrasse 215, CH-8008 Zürich.

Alger Management, Ltd. (company house number 8634056, domiciled at 78 Brook Street, London W1K 5EF, UK) is authorised and regulated by the Financial Conduct Authority, for the distribution of regulated financial products and services. La Française AM International has a signed agreement with Alger Management Ltd., whereby La Française AM International is authorized to distribute Fred Alger Management, Inc. products in Europe.